Aptevo Therapeutics Inc. (APVO)
$0.3165
Rating:
Recommendation:
Buy
| Symbol | APVO |
|---|---|
| Price | $0.3165 |
| Beta | 5.225 |
| Volume Avg. | 0.33M |
| Market Cap | 3.647M |
| Shares () | - |
| 52 Week Range | 0.3-7.2 |
| 1y Target Est | - |
| DCF Unlevered | APVO DCF -> | |
|---|---|---|
| DCF Levered | APVO LDCF -> | |
| ROE | 142.78% | Strong Buy |
| ROA | 90.43% | Strong Buy |
| Operating Margin | - | |
| Debt / Equity | 35.37% | Neutral |
| P/E | -0.09 | Neutral |
| P/B | 0.13 | Neutral |
Latest APVO news
About
Download (Excel)Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.